With the start of the procurement of clinical contract companies for the clinical study of the Fractalkine receptor antagonist KAN0440567, we now proceed from plan to action in line with Kancera’s prospectus from May 2016. Before applying for authorization of a clinical trial, we focus on the formulation (i.e. the product, e.g. capsule) of KAN0440567 that is to be given to humans. When this product is tested and ready we intend to submit the application for authorization of a clinical trial to the relevant authority (the Medical Products Agency in Sweden or equivalent authority in another EU country) and for the corresponding ethical permission.
Also in the ROR project the focus has been on the development of the product, since e.g. its purity when produced at large scale provides the foundation for both the toxicology studies and ultimately for a commercially viable production. The technological advances in the synthesis and purification of the ROR inhibitor KAN0439834 are therefore important for the entire development of the project. The recently reported findings that ROR1 is present as a target for drugs in an intractable condition called Richter’s syndrome also strengthens the project's ability to position itself on the market as a strong complement to the new drugs for leukemia and lymphoma.
In the autumn, we have also seen significant progress in the HDAC6 project, partly in the form of a successful crystallization of "Target 2" which gives us access to a molecular design drawing that facilitates the final steps in the optimization of our unique dual action (HDAC6 / Target 2) substances before the selection of a candidate drug. That we also have been able to show that Kancera’s HDAC6 inhibitors have the capacity to reduce the immunosuppressive protein PD-L1 in cancer cells confirm the published findings which support HDAC6 as a new promising immuno-oncology target for drug development.
In September, we were informed that the EU, through its research initiative Horizon2020, has chosen to give a total of about four million Euro (of which Kancera receives more than 10%, about 500,000 Euro) in grants to a leading international team of researchers that will recruit Ph.D. students in order to evaluate new approaches to combat cancer, especially with regard to how drugs can act to stop the DNA repair in cancer cells. Kancera is awarded two Ph.D. students and a grant to cover research costs, allowing us to work with cutting-edge talent in oncology to identify new project opportunities.
CEO Kancera AB
Thomas Olin, CEO